Evercore ISI lowered the firm’s price target on Twist Bioscience (TWST) to $46 from $50 and keeps an Outperform rating on the shares. The firm updated the company’s model post the fiscal Q3 report. It views the quarter as “decent” with solid gross margins. Twist has solid momentum entering fiscal 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST: